[Asia Economy Reporter Minji Lee] Kangstem Biotech announced on the 26th that it has obtained a domestic patent for its technology to develop high-performance adult stem cells, promoting proliferation, multipotency, and reprogramming.
This patent establishes standardized culture conditions through spherical growth that maintain an undifferentiated state, enabling the production of adult stem cells with CD49f-positive characteristics that promote stem cell proliferation, multipotency, and reprogramming without undergoing costly steps in the process.
The company stated, "Based on this, we will be able to manufacture highly efficient stem cell therapeutics," adding, "It can also be used for the treatment of immune-related diseases as well as neurological, cardiovascular, and skeletal system disorders."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
